Detección molecular del virus papiloma humano de alto riesgo oncogénico en muestras cervicales. Laboratorio Central de Salud Pública. Primeros Resultados

Abstract

Cervical cancer is the leading cause of cancer death in women in developing countries, with an incidence rate of 34.2 per 100,000 women and 15.7 deaths per 100,000 women in Paraguay. The sensitivity of cytology is 30-60% while molecular detection of Human Papilloma Virus (HPV) in cervical samples is over 90% for cervical intraepithelial neoplasia grade 2 (CIN II) or more. The aim of this study was to describe the frequency of detection of high-risk HPV (HR) and their distribution by age in women who attended the Hospital San Pablo, from May to August 2013. One hundred seventy cervical samples from patients who agreed to participate by signing an informed consent. The 4800 Cobas system HPV Test (Roche), which detects the HR-HPV genotypes 16 and 18, a pool of 10

Human Papilloma Virus detection through the cobas® 4800 system in women from Lima, Peru

“…The prevalence of HPV in Africa (22.1%) and America (12.9%) is estimated to be higher, in contrast to Europe (8%) and Asia (7.9%) 19 . According to the findings of the present study, the prevalence of HR-HPV is 15.2%, which is similar to that found in Paraguay (16%), lower than that reported in studies from Ecuador (25.3%) and Denmark (26.8%), but higher than that identified in investigations carried out at the USA (6.7%) and Canada (10.1%) [11][12][13][14][15] .…”

“…HR-HPV typing results and those of the referred international investigations showed that there is a higher prevalence of the group of other HR-HPVs (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68); however, in single infections, the values reported for HPV 16 stand out, followed by HPV 18 [11][12][14][15] . HPV vaccine implementation, an intervention that was incorporated into the National Vaccination Schedule since 2011 in Peru 21 , and that currently has a coverage of 98% for the first dose and 91.2% for the second, applied to girls aged from 9 to 13 years 22 , could generate a decrease in infection with certain HPV genotypes.…”

“…In Denmark (2013), Canada (2013), Paraguay (2015) and Ecuador (2016), 5,072, 4,330, 170 and 1,581 cervical samples were studied using the cobas ® 4800 system, with 26.8, 10.1, 16 and 25.3% of samples, respectively, being found to be positive for HR-HPV [12][13][14][15] . In Peru (2014), 775 HR-HPV-positive samples were obtained in women aged 17 to 79 years, out of which 242, 45 and 631 had genotypes 16, 18 and the other high risk genotypes, respectively, according to the co-bas® 4800 test 16 .…”

Detección del virus de papiloma humano por medio del método de cobas® 4800 en mujeres de Lima, Perú

“…The prevalence of HPV in Africa (22.1%) and America (12.9%) is estimated to be higher, in contrast to Europe (8%) and Asia (7.9%) 19 . According to the findings of the present study, the prevalence of HR-HPV is 15.2%, which is similar to that found in Paraguay (16%), lower than that reported in studies from Ecuador (25.3%) and Denmark (26.8%), but higher than that identified in investigations carried out at the USA (6.7%) and Canada (10.1%) [11][12][13][14][15] .…”

“…In Denmark (2013), Canada (2013), Paraguay (2015) and Ecuador (2016), 5,072, 4,330, 170 and 1,581 cervical samples were studied using the cobas ® 4800 system, with 26.8, 10.1, 16 and 25.3% of samples, respectively, being found to be positive for HR-HPV [12][13][14][15] . In Peru (2014), 775 HR-HPV-positive samples were obtained in women aged 17 to 79 years, out of which 242, 45 and 631 had genotypes 16, 18 and the other high risk genotypes, respectively, according to the co-bas® 4800 test 16 .…”